The North America atopic dermatitis drugs market size surpassed USD 8.29 billion in 2025 and is predicted to reach around USD 17.57 billion by 2035, registering a CAGR of 7.8% from 2026 to 2035.The market is growing due to the rising prevalence of eczema and increasing adoption of advanced biologics therapies.

North America Atopic Dermatitis Drugs Market Statical Scope

The atopic dermatitis drugs market in North America is witnessing strong growth due to biologics and targeted therapies are being used more frequently to treat moderate to severe eczema. Pharmaceutical firms are concentrating on expanded clinical trials, individualized treatment plans, and new drug approvals. Growing awareness of chronic skin conditions, rising healthcare spending, and rising demand for steroid-free therapies are all contributing factors to the region's market expansion.

The market is growing due to the growing incidence of atopic dermatitis, the growing use of biologic medications, and significant funding for cutting-edge dermatological treatments. The introduction of novel treatments is being accelerated by rising healthcare costs and the existence of top pharmaceutical firms. The market is expanding throughout the region due to growing demand for steroid-free treatment options and growing awareness of long-term exzema management.

North America Atopic Dermatitis Drugs Market Share, By Drug Class, 2025

• Corticosteroids - The corticosteroids segment dominated the North America atopic dermatitis drugs market with a market share of 34% in 2025, driven by its widespread use as a first-line therapy for rapid inflammation and itch relief. The segment benefits from strong physician preference, easy availability, and continuous demand for topical formulations in both mild and severe atopic dermatitis cases.
• Calcineurin Inhibitors - The calcineurin inhibitors segment emerged as the fastest-growing segment in the North America atopic dermatitis drugs market with a market share of 18% in 2025, driven by increasing adoption for long-term disease management and rising preference for steroid-sparing therapies. Growing awareness regarding side effects associated with prolonged corticosteroid use is further supporting segment growth.
• PDE4 Inhibitors - The PDE4 inhibitors segment accounted for a notable share of 12% in the North America atopic dermatitis drugs market in 2025, driven by increasing approvals of advanced non-steroidal therapies and growing demand for targeted anti-inflammatory treatments. Rising research investments and improved patient adherence are also contributing to market expansion.

North America Atopic Dermatitis Drugs Market Share, By Route of Administration, 2025

• Topical - The topical segment dominated the North America atopic dermatitis drugs market by route of administration with a market share of 52% in 2025, driven by high patient preference for easy-to-apply creams and ointments along with strong effectiveness in treating mild-to-moderate conditions. The availability of multiple branded and generic products further supports segment growth.
• Parenteral -The parenteral segment was the fastest-growing route of administration in the North America atopic dermatitis drugs market with a market share of 30% in 2025, driven by rising adoption of biologics and injectable targeted therapies for severe atopic dermatitis cases. Increasing regulatory approvals of monoclonal antibody treatments are accelerating segment demand.
• Oral - The oral segment held a considerable market share of 18% in the North America atopic dermatitis drugs market in 2025, driven by growing use of oral immunosuppressants and JAK inhibitors for moderate-to-severe disease management. Improved treatment accessibility and ongoing drug innovations are supporting segment expansion.

North America Atopic Dermatitis Drugs Market Share, By Distribution Channel, 2025

• Hospital Pharmacies - The hospital pharmacies segment accounted for a significant share of 42% in the North America atopic dermatitis drugs market in 2025, driven by increasing hospitalization and specialist-prescribed biologic treatments for severe atopic dermatitis patients. Strong availability of advanced therapies within hospital settings is supporting segment growth.
• Retail Pharmacies - The retail pharmacies segment dominated the North America atopic dermatitis drugs market by distribution channel with a market share of 46% in 2025, driven by easy accessibility of prescription and over-the-counter dermatology medications along with increasing consumer preference for convenient purchasing options. Expanding retail pharmacy chains are further strengthening market penetration.

Competitive Analysis

The competitive landscape in North America is highly consolidated with major pharmaceutical companies focusing on biologics, monoclonal antibodies, and JAK inhibitors for atopic dermatitis treatment. Key players such as Pfizer, AbbVie, Eli Lilly and Company, Regeneron Pharmaceuticals, and Sanofi are actively investing in clinical trials, strategic collaborations, and product approvals to strengthen their market presence.

Companies are also expanding patient support programs and digital dermatology services to improve treatment accessibility and competitive positioning.

Segments Covered in the Report

By Drug Class

• Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics
• Others

By Route of Administration

• Topical
• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies